GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (HKSE:02142) » Definitions » Net Loan

HBM Holdings (HKSE:02142) Net Loan


View and export this data going back to 2020. Start your Free Trial

What is HBM Holdings Net Loan?

Net Loan only applies to banks and insurance companies.


HBM Holdings Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Wang Jingsong 2101 Beneficial owner
Advantech Capital L.p.
Pang Kee Chan Hebert
Golden Link Investment Limited
Advantech Capital Partners Ltd.
Advantech Master Investment Limited
Astrazeneca Plc 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Owap Investment Pte Ltd 2101 Beneficial owner
Advantech Capital Holdings Ltd.
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you